33.87

1.62% 0.54

After Hours: 33.85 -0.02 -0.06%

Celldex Therapeutics Inc (CLDX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Celldex Therapeutics Inc stock is traded at $33.87, with a volume of 971.63K. It is up +1.62% in the last 24 hours and up +14.77% over the past month. Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Previous Close:

$33.33

Open:

$33.58

24h Volume:

971.63K

Relative Volume:

0.99

Market Cap:

$2.66B

Revenue:

$1.55M

Net Income/Loss:

$-258.76M

P/E Ratio:

-8.6951

EPS:

-3.8953

Net Cash Flow:

$-213.66M

1W Performance:

+4.50%

1M Performance:

+14.77%

6M Performance:

+23.88%

1Y Performance:

+84.38%

1-Day Range:

$33.49

$34.26

1-Week Range:

$31.96

$34.26

52-Week Range:

$17.45

$34.52

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name

Celldex Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

908-200-7500

Address

53 FRONTAGE ROAD, HAMPTON

Employee

198

Twitter

@search?q=celldex

Next Earnings Date

2024-11-04

Latest SEC Filings

CLDX's Discussions on Twitter

Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLDX Celldex Therapeutics Inc	33.87	2.62B	1.55M	-258.76M	-213.66M	-3.8953
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-26	Upgrade	Wolfe Research	Peer Perform → Outperform
Oct-21-25	Initiated	Mizuho	Outperform
Oct-13-25	Initiated	Barclays	Underweight
Apr-28-25	Initiated	Canaccord Genuity	Buy
Mar-20-25	Initiated	Morgan Stanley	Overweight
Feb-13-25	Initiated	UBS	Buy
Oct-07-24	Initiated	Citigroup	Buy
Sep-30-24	Initiated	Goldman	Neutral
Sep-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-18-24	Initiated	Stifel	Buy
Jun-11-24	Initiated	Wolfe Research	Outperform
Dec-20-23	Initiated	TD Cowen	Outperform
Nov-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Aug-22-23	Initiated	Wells Fargo	Underweight
Sep-17-21	Initiated	Jefferies	Buy
Sep-10-21	Initiated	SVB Leerink	Outperform
Jul-22-21	Initiated	Guggenheim	Buy
Feb-21-20	Initiated	Cantor Fitzgerald	Overweight
Aug-01-17	Resumed	H.C. Wainwright	Buy
Nov-07-16	Initiated	Aegis Capital	Buy
Mar-08-16	Downgrade	Jefferies	Buy → Hold
Mar-07-16	Downgrade	Guggenheim	Buy → Neutral
Mar-07-16	Downgrade	Leerink Partners	Outperform → Mkt Perform
Mar-07-16	Downgrade	Wedbush	Outperform → Neutral
Mar-01-16	Initiated	H.C. Wainwright	Buy
Aug-11-15	Reiterated	Brean Capital	Buy
Aug-11-15	Reiterated	Oppenheimer	Outperform
Aug-11-15	Reiterated	ROTH Capital	Buy
Jun-02-15	Reiterated	WBB Securities	Strong Buy
Nov-17-14	Reiterated	ROTH Capital	Buy
Mar-04-14	Reiterated	Oppenheimer	Outperform
Jul-08-13	Reiterated	Cantor Fitzgerald	Buy
Mar-08-13	Reiterated	Cantor Fitzgerald	Buy
Feb-26-13	Reiterated	Oppenheimer	Outperform
Jan-10-13	Reiterated	Cantor Fitzgerald	Buy
Oct-02-12	Reiterated	Oppenheimer	Outperform
Sep-14-12	Reiterated	Cantor Fitzgerald	Buy

View All

Celldex Therapeutics Inc Stock (CLDX) Latest News

Apr 15, 2026

Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment - Yahoo Finance

Apr 15, 2026

Apr 14, 2026

Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN

Apr 14, 2026

CLDX: Barzolvolimab shows strong, durable efficacy in urticaria with pivotal phase III data due Q4 - TradingView — Track All Markets

Apr 14, 2026

Apr 13, 2026

Celldex to Present at Upcoming Investor Conference - The Manila Times

Apr 13, 2026

Apr 10, 2026

Celldex Therapeutics announces public offering of common stock - MSN

Apr 10, 2026

Apr 09, 2026

A Look At Celldex Therapeutics (CLDX) Valuation After Equity Raise And New Barzolvolimab Data - Sahm

Apr 09, 2026

Apr 08, 2026

Precision Trading with Celldex Therapeutics Inc. (CLDX) Risk Zones - Stock Traders Daily

Apr 08, 2026

Apr 07, 2026

RSI Check: Why is Vistagen Therapeutics Inc stock going downBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn

Apr 07, 2026

Celldex Therapeutics Closes $345M Public Stock Offering - National Today

Apr 07, 2026

Apr 06, 2026

Celldex closes $345 million stock offering By Investing.com - Investing.com Australia

Apr 06, 2026

Celldex Therapeutics Completes $345 Million Public Offering of Common Stock - Quiver Quantitative

Apr 06, 2026

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - marketscreener.com

Apr 06, 2026

Apr 05, 2026

Did Celldex’s (CLDX) US$300 Million Equity Raise to Fund Barzolvolimab Just Shift Its Investment Narrative? - Sahm

Apr 05, 2026

Apr 04, 2026